Melfalano Pharmexon

Melphalan, the active ingredient in Melfalano Pharmexon, is an alkylating agent presented as a sterile solution for intraarterial and intravenous use. It is employed in the treatment of certain blood cancers and solid tumors, notably multiple myeloma and ovarian cancer, in adult patients.

GNH USA supplies Melfalano Pharmexon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for clinical use. Timely logistics and cold‑chain management ensure product integrity across global markets.

Melfalano Pharmexon (melphalan) acts as an alkylating agent targeting rapidly dividing cancer cells.

Multiple Myeloma: reduces malignant plasma cell proliferation, helps achieve remission and prolongs progression‑free survival. Ovarian Cancer: used in combination with platinum‑based agents to increase cytotoxic effect on ovarian tumor cells. Bone Marrow Conditioning: employed in high‑dose regimens prior to autologous stem cell transplantation to eradicate residual disease. Other Solid Tumors: occasionally investigated in experimental protocols for melanoma or neuroblastoma.

Melfalano Pharmexon may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea - Vomiting - Bone marrow suppression (neutropenia, anemia, thrombocytopenia) - Alopecia

Serious or Rare Side Effects: - Secondary malignancies - Severe infections - Pulmonary toxicity - Renal toxicity

Prior to initiating therapy, clinicians should assess baseline organ function and monitor patients closely for toxicity.

Monitor blood counts: perform regular CBC to detect neutropenia and anemia. Assess renal function: adjust dose in patients with impaired kidney function. Evaluate hepatic function: monitor liver enzymes before and during therapy. Avoid use in active infections: postpone treatment until infection resolved. Contraindicated in known hypersensitivity to melphalan or excipients. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Melphalan can interact with several concomitant medicines, requiring careful management.

Major Interactions (Avoid): - Live vaccines: increased risk of severe infection. - Other alkylating agents: additive bone marrow toxicity. - High‑dose radiation therapy: heightened tissue damage.

Moderate Interactions (Monitor Closely): - Anticoagulants: potential for increased bleeding. - Nephrotoxic drugs: may exacerbate renal impairment. - Immunosuppressants: heightened infection risk.